BP327

General Information


DRACP ID  DRACP00482

Peptide Name   BP327

Sequence  CREKAKKLFKKILKKL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Coupling peptide



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=74.7±8.8µM MTT assay 48h 1
CAPAN-1 Pancreatic ductal adenocarcinoma Carcinoma IC50=76.2±0.8µM MTT assay 48h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50=74.5±4.1µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00482

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C92H168N26O19S

Absent amino acids  DGHMNPQSTVWY

Common amino acids  K

Mass  224231

Pl  11.19

Basic residues  8

Acidic residues  1

Hydrophobic residues  6

Net charge  7

Boman Index  -3483

Hydrophobicity  -76.88

Aliphatic Index  103.75

Half Life 
  Mammalian: 2.8 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24480922

Title  Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties

Doi 10.1039/c3ob42422g

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_10332

DRACP is developed by Dr.Zheng's team.